A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
Public ClinicalTrials.gov record NCT02983227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
Study identification
- NCT ID
- NCT02983227
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 496 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 76 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2016
- Primary completion
- Jul 16, 2019
- Completion
- Jul 16, 2019
- Last update posted
- Aug 2, 2020
2016 – 2019
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Associates, P.C. | Glendale | Arizona | 85306 | — |
| Medvin Clinical Research | Covina | California | 91723 | — |
| TriWest Research Associates, LLC | El Cajon | California | 92020 | — |
| Saint Jude Heritage Medical Grp | Fullerton | California | 92835 | — |
| RASF-Clinical Research Center | Boca Raton | Florida | 33486 | — |
| Clinical Research of West Florida | Clearwater | Florida | 33765 | — |
| Medication Management | Greensboro | North Carolina | 27408 | — |
| Oregon Health & Science Uni | Portland | Oregon | 97239 | — |
| Metroplex Clinical Research Centre | Dallas | Texas | 75231 | — |
| Baylor Research Inst. | Dallas | Texas | 75246 | — |
| Accurate Clinical Research | Houston | Texas | 77089 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02983227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02983227 live on ClinicalTrials.gov.